Worth reading
—
Scored from 0 of 4 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
670
¥ million (year-on-year change in operating profit)Wording
Avoiding a definitive answer
How definitive the wording is.Resolutions for the General Meeting of Shareholders
23rd Annual General Meeting of Shareholders| Item | Details |
|---|---|
| Type of shareholders' meeting | 23rd Annual General Meeting of Shareholders |
Items this document does not state (5)
Date and timeMatters for resolutionShareholder ProposalDirector nomineePercentage voting in favor
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that research and development expenses are expected to increase by ¥678 million year on year, contributing to the wider operating loss. This includes ¥333 million in expenses reclassified from prepayments made in the previous fiscal year, which will not involve a cash outflow. The increase in research and development expenses is attributed to higher research and development funding to prepare for clinical trials of BP2202.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.